Monopar Therapeutics Inc(MNPR) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -2.34 | Insider Own | 41.33% | Shs Outstand | 6.7M | Perf Week | -0.92% |
| Market Cap | 0.48B | Forward P/E | - | EPS next Y | 17.27% | Insider Trans | -1.59% | Shs Float | 3.9M | Perf Month | -9.74% |
| Enterprise Value | 0.35B | PEG | - | EPS next Q | -0.82 | Inst Own | 77.32% | Short Float | 28.65% | Perf Quarter | -33.63% |
| Income | -0.02B | P/S | - | EPS this Y | -60.91% | Inst Trans | -0.25% | Short Ratio | 6.23 | Perf Half Y | 37.89% |
| Sales | 0.00B | P/B | 3.69 | EPS next 5Y | -0.2% | ROA | -18.9% | Short Interest | 1.13M | Perf YTD | 10.12% |
| Book/sh | 19.5 | P/C | 3.59 | EPS past 3/5Y | 23.5% 8.44% | ROE | -19.5% | 52W High | -42.39% ($124.82) | Perf Year | -14.55% |
| Cash/sh | 20.01 | P/FCF | - | Sales past 3/5Y | - | ROIC | -13.63% | 52W Low | 43.62% ($50.07) | Perf 3Y | 3026.52% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 29.73% | Gross Margin | - | Volatility(W/M) | 4.79% 5.18% | Perf 5Y | 199.63% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 4.06 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 33.56 | EPS Q/Q | -77.41% | Profit Margin | - | RSI (14) | 35.6 | Recom | 1.3 |
| Dividend Gr. 3/5Y | - | Current Ratio | 33.56 | Sales Q/Q | - | SMA20 | -3.79% ($74.74) | Beta | 1.61 | Target Price | $129.91 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/8/12 | SMA50 | -21.74% ($91.89) | Rel Volume | 0.9 | Prev Close | $73.39 |
| Employees | 22 | LT Debt/Eq | 0 | EPS/Sales Surpr. | 4.19% - | SMA200 | -6.89% ($77.23) | Avg Volume(3M) | 0.18M | Price | $71.91 |
| IPO | 2019/12/19 | Option/Short | No/Yes | Trades | 2879 | Volume | 163,116 | Change | -2.02% |
🧬 Monopar Therapeutics (MNPR) is a US clinical-stage biotech company focused on rare diseases and radiopharmaceuticals. Its core pipeline includes ALXN1840, a candidate therapy for Wilson's disease, and the MNPR-101 radiopharmaceutical platform, which targets advanced cancers. In this structure, regulatory approvals and clinical progress are the key drivers of the company's value.
Over the past 1 year, roughly in the middle
42% below its 1-year high.
Traded about as much as usual. That is 90% of its average volume.
MNPR has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -60.9% this year.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +199.6%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
28.6% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #226 of 594 in the industry
Based on market cap of $483M.
RGNX#223 Regenxbio Inc $489M PER - 
FTH#224 Faeth Therapeutics Inc $485M PER - 
BLSM#225 BlossomHill Therapeutics Inc $483M PER - MNPR#226 Monopar Therapeutics Inc $483M PER - 
EPRX#227 Eupraxia Pharmaceuticals Inc $471M PER - 
FAQ
What kind of company is MNPR?
MNPR belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of MNPR?
The market cap of MNPR is approximately $483M, ranking 3,192 within its sector.
What is the 52-week high and low for MNPR?
MNPR has recorded a 52-week high of $124.82 and a low of $50.07.
